Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone512-279-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.85 million
Profitability
Miscellaneous
Employees215
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery Inc (NASDAQ:APEN) issued its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.10. The biotechnology company earned $15.79 million during the quarter, compared to analysts' expectations of $16.56 million. Apollo Endosurgery had a negative return on equity of 126.08% and a negative net margin of 69.89%. View Apollo Endosurgery's Earnings History.
When is Apollo Endosurgery's next earnings date?
What price target have analysts set for APEN?
2 analysts have issued 1-year price targets for Apollo Endosurgery's shares. Their forecasts range from $3.00 to $4.00. On average, they expect Apollo Endosurgery's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price. View Analyst Price Targets for Apollo Endosurgery.
What is the consensus analysts' recommendation for Apollo Endosurgery?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery.
Has Apollo Endosurgery been receiving favorable news coverage?
Media stories about APEN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Apollo Endosurgery.
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Accuray (ARAY), Inovio Pharmaceuticals (INO), Soliton (SOLY), Apyx Medical (APYX), SeaSpine (SPNE), Vapotherm (VAPO), Neuronetics (STIM), Repro-Med Systems (REPR), RenovaCare (RCAR), Cytosorbents (CTSO), iCAD (ICAD), T2 Biosystems (TTOO), BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS) and Liquidia Technologies (LQDA).
What other stocks do shareholders of Apollo Endosurgery own?
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 56)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
- Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $2.96.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $61.96 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.View Additional Information About Apollo Endosurgery.
What is Apollo Endosurgery's official website?
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
